Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials
Tamoxifen appears to be the most effective strategy for preventing bicalutamide-induced breast events, with radiotherapy serving as a viable alternative, and anastrozole offering no benefit. Further large-scale, high-quality studies are needed to confirm these findings and refine preventive treatment recommendations.
Authors
- Arcangelo Barbonetti (ORCID: https://orcid.org/0000-0002-6888-9585)
- Antonella Ferranti
- C Capuano
- Daniele Tienforti (ORCID: https://orcid.org/0000-0002-9359-7955)
- Luca Spagnolo
- C Moretto
- Camilla Tonni
- Vittoria Donatelli
- Gennaro Puocci
Institutions
- University of Teramo (IT)
- University of L'Aquila (IT)
- Danieli (Italy) (IT)
Publication Details
- Journal
- Journal of Endocrinological Investigation
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1007/s40618-025-02583-8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi dell'Aquila